Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Infection susceptibility increased? 35 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 35 reports of Infection susceptibility increased have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.0% of all adverse event reports for TOCILIZUMAB.

35
Reports of Infection susceptibility increased with TOCILIZUMAB
0.0%
of all TOCILIZUMAB reports
8
Deaths
17
Hospitalizations

How Dangerous Is Infection susceptibility increased From TOCILIZUMAB?

Of the 35 reports, 8 (22.9%) resulted in death, 17 (48.6%) required hospitalization, and 2 (5.7%) were considered life-threatening.

Is Infection susceptibility increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 35 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Infection susceptibility increased?

ADALIMUMAB (179) ETANERCEPT (160) OCRELIZUMAB (118) METHOTREXATE (95) PREDNISONE (67) DIMETHYL (64) MYCOPHENOLATE MOFETIL (64) PREDNISOLONE (62) SECUKINUMAB (59) TOFACITINIB (57)

Which TOCILIZUMAB Alternatives Have Lower Infection susceptibility increased Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Infection susceptibility increased Reports All Drugs Causing Infection susceptibility increased TOCILIZUMAB Demographics